CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
← catalyst calendarSponsored by Candel Therapeutics, Inc. (industry) · CADL — their whole pipeline →. With NYU Langone Health.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
90actual
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-13 | actual | When the study began enrolling |
| Primary completion | 2024-12-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2020-07-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Small Cell Lung Cancer
Intervention
- Biological: Aglatimagene besadenovec — also filed as CAN-2409, AdV-tk
Primary outcomes
what the primary-completion date above is the date OFResponse rate
measured 12 months
Safety graded by CTCAE version 5.0
measured 12 weeks
Permalink · CADL's whole pipeline · Catalyst calendar · Every registered study · What changed